Chemomab Therapeutics (CMMB) vs Ensysce Biosciences (ENSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Ensysce Biosciences is the larger company by market cap ($10.3 million vs $10.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMMB | ENSC |
|---|---|---|
| Share price | $1.38 | $0.527 |
| Market cap | $10.11M | $10.25M |
| 1-day change | -0.72% | +15.07% |
| YTD return | -16.36% | — |
| 1-year return | -59.05% | — |
| 5-year return | -96.20% | — |
| EPS (TTM) | $-1.04 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.50 | $2.75 |
| 52-week low | $1.05 | $0.23 |
| Distance from 52-week high | -60.57% | -80.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +262.32% | +1465.46% |
| Average volume | 113.36K | 14.43M |
| Shares outstanding | 7.33M | 19.46M |
| Employees | — | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
CMMB vs ENSC FAQ
Which is bigger, Chemomab Therapeutics or Ensysce Biosciences?
Ensysce Biosciences (ENSC) is larger, with a market capitalization of $10.25M compared with $10.11M for Chemomab Therapeutics (CMMB).
Are Chemomab Therapeutics and Ensysce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.